Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation

  • Zhijie Deng
  • , Jerrel Catlett
  • , Youngeun Lee
  • , Qiong Wu
  • , Zhongli Xu
  • , Ling Xie
  • , Xian Chen
  • , Yan Xiong
  • , H. Ümit Kaniskan
  • , Jian Jin

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Proteolysis Targeting Chimeras (PROTACs) represent promising therapeutic modalities for degrading disease-causing proteins. However, the development of effective PROTACs has been limited by the availability of suitable E3 ligase ligands. In this study, we demonstrate for the first time that SPOP, an unexplored E3 ligase, can be recruited to degrade target proteins of interest. We developed a bridged PROTAC strategy and successfully discovered a proof-of-concept PROTAC degrader 9 (MS479), which recruits the E3 ligase SPOP by directly binding its substrate GLP as a bridge protein. This approach facilitates the polyubiquitination and subsequent degradation of BRD4/3/2 by the 26S proteasome. 9 effectively reduced the protein level of BRD4 short isoform in a time-, concentration-, GLP-, SPOP-, and ubiquitin-proteasome system (UPS)-dependent manner. Additionally, 9 effectively inhibited the proliferation of colorectal cancer (CRC) cells. Overall, our study expands the limited repertoire of the E3 ligases that can be harnessed for targeted protein degradation.

Original languageEnglish
Pages (from-to)8634-8647
Number of pages14
JournalJournal of Medicinal Chemistry
Volume68
Issue number8
DOIs
StatePublished - 24 Apr 2025

Fingerprint

Dive into the research topics of 'Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation'. Together they form a unique fingerprint.

Cite this